An indirect comparison of long-term efficacy of every-two-week dosing versus recommended dosing of ixekizumab in patients who had sPGA > 1 at week 12.

CONCLUSIONS: Among patients who did not have clear or almost clear skin at Week 12, nearly 30% more patients treated continuously with ixekizumab Q2W in IXORA-P had clear or almost clear skin at Week 52 when compared indirectly with those treated with labeled psoriasis dosing in integrated UNCOVER studies. PMID: 31545506 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31545506?dopt=Abstract

Source: The British Journal of Dermatology - September 22, 2019 Category: Dermatology Authors: Papp K, Maari C, Cauthen A, Gooderham M, Spelman L, Yamanaka K, Polzer P, Zhang L, Osuntokun O, Augustin M Tags: Br J Dermatol Source Type: research